Singulair Switch Among Merck's OTC Possibilities
This article was originally published in The Tan Sheet
Executive Summary
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
You may also be interested in...
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.
Merck's Frazier Promoted To CEO To Drive Post-Schering Success
Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.